NeOnc Technologies

Nasdaq: NTHI · SEC EDGAR filings

Results on file1
Average 24h move−20.91%across 1 result with a complete 24h price
1 resultNeOnc Technologies
Met endpoint

NEO100

Phase 2 Recurrent IDH1-Mutant High-Grade Glioma

NeOnc Technologies NTHI

24h stock move −20.91%

For information only. Not investment or medical advice. Prices are historical, from consolidated market data, and may contain errors. Always check the original source.